中等症・重症喘息：IL-9抗体：MEDI-528 phase II治験
2010年 05月 22日
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced today that it has purchased from the Genaera Liquidating Trust certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca’s subsidiary, MedImmune. MEDI-528 is currently in a 320-patient Phase II study for moderate-to-severe asthma.
Press Release Source: Ligand Pharmaceuticals Incorporated On Friday May 21, 2010, 8:00 am EDT